Biolargo Stock Price, News & Analysis

BioLargo (OTCQX:BLGO) will host an investor webcast and conference call on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET to review results for the quarter ended September 30, 2025, discuss recent milestones, and hold a Q&A session.

Live access: register at the webcast page at least 15 minutes early. Teleconference numbers and participant code are provided for domestic and international callers. A replay is available through February 14, 2027, and the webcast replay plus presentation materials will be posted on BioLargo's Investor Relations page at www.biolargo.com/investor-relations.

BioLargo (OTCQX:BLGO) subsidiary Clyra Medical Technologies signed an exclusive stocking distribution agreement with Advanced Solution to distribute ViaCLYR™ nationwide in the United States.

ViaCLYR™ uses Clyra's proprietary Clyrasept™ copper-iodine complex, described as antimicrobial and shown to have safety, efficacy, biocompatibility, and cost-effectiveness in FDA-cleared applications. The product is scheduled for market launch in early 2026. The alliance pairs Clyra's technology with Advanced Solution's national distribution network and clinical training capabilities to accelerate adoption across healthcare providers.

BioLargo (OTCQX:BLGO) announced a breakthrough upgrade to its patented Aqueous Electrostatic Concentrator (AEC) that cuts energy use by more than 90% for large-scale PFAS treatment versus prior AEC generations. The company cites prior May 2025 data showing up to 80% total life-cycle cost savings versus carbon technologies and claims non-detect PFAS removal <1 ppt in drinking and brackish water.

Example: a 1,000 gpm municipal system could see monthly energy costs fall from ~$208,000 to ~$15,700 (>$2.3M annual savings at $0.15/kWh). An industrial test showed 88% energy reduction; waste is reported as 1/40,000th that of carbon systems. A first commercial installation in New Jersey is nearing operation.

BioLargo (OTCQX: BLGO) announced that its CEO presented at the LD Micro Main Event XIX on October 20, 2025 at the Hotel del Coronado in San Diego.

The presentation covered Cellinity battery cell technology, BioLargo’s role in the global AI infrastructure investment cycle, and a general corporate update. The company filed a Form 8-K on October 20, 2025 to provide the presentation materials, which are available online at the company’s SEC filings page: https://www.biolargo.com/sec-filings.

BioLargo (OTCQX:BLGO) invites professionals to the 16th Annual Sustain SoCal Energy Event on October 16, 2025 at The Cove at UCI Beall Applied Innovation in Irvine, CA.

The full-day conference, themed "Energy in Perspective," runs 9:00 AM–7:00 PM and features a keynote by David Hayes, discussions on nuclear energy, hydrogen, AI-driven residential engagement, local energy programs, and the 2025 Sustainability Awards.

BioLargo is a sponsor and speaker and will highlight its #Cellinity battery technology for grid-scale energy storage. Registration and event details are available on the Sustain SoCal event page.

BioLargo (OTCQX:BLGO) will present its Cellinity battery technology at LD Micro Main Event XIX on Monday, October 20, 2025 at 2:00 p.m. PT at the Hotel del Coronado in San Diego.

Management says Cellinity is a battery storage solution for AI infrastructure that eliminates the need for rare earth elements. The company emphasizes applications in AI data centers and grid-scale storage and notes related capabilities in water reuse, PFAS remediation, odor/VOC control, and on-site energy storage. A live webcast is available at https://ldmicrocasts.com/#register.

The release includes a Safe Harbor statement about forward-looking expectations and refers investors to the company's SEC filings for risks.

BioLargo (OTCQX:BLGO) announced that its subsidiary Clyra Medical is advancing toward commercial launches and international expansion for its ViaCLYR wound irrigation and surgical products, targeting initial U.S. and select EMEA sales in late 2025 or early 2026. Key activities include distributor agreements for EMEA and U.S. reach, completion of package and label design, product claim finalization, and ongoing stability, packaging and process validation ahead of standard FDA submission and review. Clyra has secured $7.5 million in capital to support manufacturing readiness and rollouts. Market context cites a $732 million 2024 wound irrigation market with 3.4% CAGR to 2034.